Dislocation

Dislocation — what exactly happened to the price

The Cigna Group has a real, dated dislocation, but a moderate one. Shares fell 33.4% from a $366.85 peak (16 Sep 2024) to a $244.41 trough (31 Oct 2025) — 410 days, at least four distinct down-legs on identifiable managed-care and pharmacy-benefit triggers, not one crash. Traded volume elevated only to 2.1x its pre-peak median. Its notable feature: the price fell while forward earnings estimates held and rose — the framework's mispricing signature is present; the deep forced-selling washout is not.

The drawdown, quantified

Source: peak, trough, current and depth are the deterministic capitulation gauge (derived: fit_features.capitulation_gauge.drawdown); prices from the company price feed, as reported.

Source: company price feed, month-end closes, as reported; peak and trough dates per fit_features.capitulation_gauge.

The fall is not one leg. From the September 2024 peak the stock lost roughly a quarter into late December 2024, recovered almost fully to $340 by April 2025, gave that back into a July 2025 low of $267, bounced to $311 by early October, then set its trough of $244.41 the day after third-quarter results. Each leg round-tripped part of the prior one; the drawdown is a series of repricings, not a single capitulation. Off the trough the stock has recovered 16.5% to $284.85, leaving it 22.3% below the peak.

The trigger — four dated legs

The event legs separate cleanly from drift. The initial September–October 2024 slide off $366.85 carried no company-specific event and normal volume — that first ~14% is drift, not the moment. What follows is four datable adverse events.

Source: price feed for levels and one-day/leg moves; triggers per company earnings calls (cited below) and reported market events.

Leg 1 — the industry PBM leg (Sept–Dec 2024). The largest leg is not Cigna-specific. Between early December 2024 and 19 December the stock fell from $330 to $274.80 (its 19 Dec close), part of a sector-wide selloff in pharmacy-benefit owners triggered by the 4 December killing of UnitedHealthcare's CEO, a bipartisan bill to force PBM–pharmacy divestiture, and the president-elect's public "knock out the middleman" remarks. These are reported market events, not Cigna filings; the corpus holds no primary Cigna document for them, so they are stated as such. This is the whole-industry repricing the framework treats as a promising setup — the mechanism is political and regulatory, applied to every large PBM at once.

Leg 2 — Q4-2024 results, 30 January 2025 (−6.7%). Alongside strong 2024 results, Cigna established a 2025 adjusted-EPS outlook of "at least $29.50" and disclosed that its stop-loss medical-care ratio would run above target for full-year 2025 [1], citing elevated medical costs in the stop-loss product within Cigna Healthcare [2]. The reaction was a first-order medical-cost worry, shared across the managed-care group that quarter.

Leg 3 — Q2-2025 results, 31 July 2025 (−10.2%). Management described elevated medical costs "throughout the year" [3] and noted stop-loss "remained elevated in the quarter, consistent with expectations," while reaffirming the full-year outlook of at least $29.60 per share [4]. The stock fell 10.2% to $267.38 on maintained — not cut — guidance: a de-rating of the multiple against a cost fear, not a cut to the number.

Leg 4 — Q3-2025 results, 30 October 2025 (−17.4%), the trough. The deepest single day paired a clear beat — revenue of $69.7 billion and adjusted EPS of $7.83 [5] — with a structural disclosure that reset forward expectations. Cigna announced a new rebate-free pharmacy model and said it expects "margin pressure within our Pharmacy Benefit Service segment over the next two years," while again reaffirming the 2025 outlook of at least $29.60 [6]. Management was explicit that "for 2026, Evernorth will not be on that long-term growth algorithm" [7]. The trigger is a change to the two-year earnings trajectory of the pharmacy-benefit segment (roughly 30% of enterprise earnings), not a miss on the current year — the stock closed at $247.10, with the $244.41 trough the following day.

The fear gauge

Source: volume-spike multiple is the deterministic gauge (derived: fit_features.capitulation_gauge.volume_spike); single-day multiple and pre-peak median computed from the price feed.

The measured capitulation gauge is 2.12x — the maximum 20-day average volume through the peak-to-trough leg, divided by the median daily volume in the 180 days before the peak. That is moderate, not a washout: it says traded volume ran roughly twice normal at its most sustained, well short of the 3–5x sustained surge that marks emotion-driven forced selling.

Two details qualify it. First, the 20-day volume peak occurred not at the price trough but in the December 2024 industry-PBM leg (the 20-day window ending 23 December 2024) — the most crowded selling was the sector-political episode, not a Cigna-specific panic. Second, the single most violent day, 30 October 2025, traded 9.3 million shares — about 7.4x the pre-peak median — but that spike did not sustain into a multi-week washout. The pattern reads as repeated bouts of anxious-to-orderly repricing rather than one exhaustive capitulation.

Who was selling

The evidence on seller composition is thin, and where it is absent the tab says so rather than infer. Reported short interest is unavailable for CI in this corpus — the short-interest feed returned no position rows, so short-interest level, change, and days-to-cover cannot be quantified here. No forced or structural sellers are disclosed in the filings: no index deletion, no fund-liquidation event, no cluster of insider sales tied to the drawdown surfaced in the corpus.

What the data does support is that this was a liquid, orderly market throughout. The stock trades roughly $463 million a day (20-day average), zero zero-volume days over the last 60 sessions, with a small median daily range near 0.9% — a large-cap where a seller could exit without moving the tape. The character of the selling is therefore best described by the volume gauge above (moderate, sector-led) and by the fact that the largest leg was a whole-industry political repricing that hit every PBM owner at once — anchored and macro-driven selling more than informed, name-specific exit — but the direct seller-identity evidence (short interest, 13F flow) needed to say so with confidence is not in this corpus.

Estimates versus price — the timing

This is where Cigna departs from the classic dislocation. In the framework's canonical case the earnings estimate is cut and the stock falls with it. Here the estimate did not fall. Cigna established its 2025 outlook at "at least $29.50" in January 2025 [8], raised it to "at least $29.60" and reaffirmed that figure at every quarter of the drawdown [9], then set a 2026 outlook of at least $30.35, reiterated in January 2026 [10]. Guidance rose across the fall.

Source: sell-side consensus, current snapshot (data/sp/estimates.json, eps_normalized mean); point-in-time revision history is not in the corpus.

Consensus forward EPS in the current snapshot rises every year — $29.65 for 2025 to $41.92 for 2029 — and consensus forward free cash flow (per fit_features.consensus_forward_yield) runs $9.0 billion in 2026 rising to $10.2 billion in 2027, yields of 11.8% and 13.3% on the current $76.5 billion market cap. Against a price down 33.4%, the earnings line the sell side underwrites did not fall one-for-one; the multiple did most of the work. The timing caveat is a genuine data gap: this run holds only the current estimate snapshot, not the dated CapIQ revision series, so the exact date-by-date path of consensus cannot be plotted — the claim rests on the guidance progression, which is dated and cited, and on the direction of the current forward curve.

The framework's signature — a price fall that outruns the change in the earnings estimate — is therefore present, and unusually stark: the price fell 33% while the guided and consensus earnings numbers moved higher. Whether that gap is a mispricing or a fair discount for a lower-quality two-year PBM trajectory is not this tab's question — that is the work of the Damage Math and Yield tabs. What happened is clear: a moderate, multi-leg de-rating on real but datable triggers, with the earnings estimate intact.